Figure 4.
Inhibition of p38 MAPKs potentiates TRAIL-induced apoptosis in androgen receptor-positive and BAX-expressing prostate cancer cells. (a) BAX-deficient DU145 cells, and those stably expressing BAX (see inset for immunoblot of expressed proteins), were treated with TRAIL (500 ng/ml)±SB203580 (50 μM) and assayed for cell death by annexin V/PI staining and flow cytometry. (b, c) LNCaP prostate cancer cells, which express both BAX and BAK, as well as the androgen receptor and prostate-specific antigen,41,42 were similarly immunoblotted for MCL-1 and assayed for their sensitivity to TRAIL±SB203580